Farallon Capital Management
http://www.faralloncapital.com/farallon/index.htmFarallon Capital Management is an investment firm than manages equity capital for institutions and high net worth individuals. The firm's institutional investors are primarily college endowments and foundations. Farallon primarily invests in businesses and securities that are undergoing change or will appreciate because of an expected event which includes mergers, restructurings, recapitalizations or other major changes. The firm seeks to build strong relationships with the management of companies in which it invests.
View Older Stories View More Recent Stories
-
Toshiba says no evidence it pressured Harvard over AGM vote
-
Form 13F-NT Farallon Capital Europe For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
-
Form SC 13G/A Broadmark Realty Capital Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A AMYRIS, INC. Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A DermTech, Inc. Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A ENANTA PHARMACEUTICALS Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A PROGENICS PHARMACEUTICAL Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Savara Inc. Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Protagonist Therapeutics Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Hedge fund Indaba pushes Benefitfocus to put itself up for sale
-
Imago BioSciences to Participate in Upcoming Investor Conferences
-
Orchard Therapeutics Plc (ORTX) Reports $150M Strategic PIPE Financing from 24.12M Share Sale at $6.22/Sh
-
Orchard Therapeutics Announces $150 Million Strategic Financing
-
Orchard Therapeutics Announces $150 Million Strategic Financing
-
Inivata Raises $35 million in Second Close of Series C Financing
-
Imago BioSciences Appoints Enoch Kariuki to Board of Directors
-
BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Signs Agreements to Acquire Leading Digital Musculoskeletal Company, Raise $70 Million Through Private Placement
-
Design Therapeutics Secures $125 Million in Series B Financing to Advance Pipeline of Genomic Medicines for Nucleotide Repeat Expansion Disorders
-
DarioHealth (DRIO) Announces Acquisition of Leading Digital Musculoskeletal Company Upright Technologies and $70 Million Financing
-
DarioHealth Announces Acquisition of Leading Digital Musculoskeletal Company Upright Technologies and $70 Million Financing
-
Toshiba regains Tokyo exchange's top category amid calls for better governance
-
Rayonier (RYN) Reports Election of Meridee A. Moore and Matthew J. Rivers to Board
-
Rayonier Announces the Election of Meridee A. Moore and Matthew J. Rivers to its Board of Directors
-
Imago BioSciences Appoints Matthew J. Plunkett as Chief Financial Officer
-
Beam Therapeutics Inc. (BEAM) Announces $260 Million Common Stock Investment from Multiple Investors
-
Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors
-
Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors
-
Form SC 13D/A Playa Hotels & Resorts Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Generation Bio Co. Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Tiga Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing January 14, 2021
-
Imago BioSciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds
-
Flowonix Medical, Inc. and SWK Holdings Corporation Announce Closing of $33 Million Financing
-
U.S. hedge fund Farallon joins top Toshiba shareholder in call for EGM
-
Farallon requests Toshiba Corporation Convene an EGM to Explain and Seek Shareholder Approval Regarding Significant Changes to the Toshiba Next Plan Relating to a New One Trillion Yen Growth Investing
-
SomaLogic Adds $81M to Series A Financing Totaling $214M
-
SomaLogic Adds $81M to Series A Financing Totaling $214M
-
Imago BioSciences’ Bomedemstat (IMG-7289) Shows Sustained Clinical Activity in Phase 2 Interim Data for Treatment of Myelofibrosis
-
Imago BioSciences Expands Phase 2 Clinical Trial of Bomedemstat (IMG-7289) for the Treatment of Myelofibrosis into Hong Kong
-
Tiga Acquisition Corp. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Units
-
SomaLogic Closes $121M Series A Financing Led by Casdin Capital
-
SomaLogic Closes $121M Series A Financing Led by Casdin Capital
-
Form SC 13D/A Playa Hotels & Resorts Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
IPO for SPAC Tiga Acquisition (TINV) Opens Modestly Higher
-
Tiga Acquisition Corp. Announces Pricing of $240,000,000 Initial Public Offering
-
Imago BioSciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference

